Clinical trials: Sclerosis, Multiple
Multiple Sclerosis
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
The aim of this multicentre, randomised, double-blind, placebo-controlled study is to evaluate the efficacy and safety of supplementary treatment with cholecalciferol (vitamin D3) in subjects with relapsing multiple sclerosis (R…
- Trial name
- CHOLINE (NCT01198132)
- Testing
- Cholecalciferol (Vitamin D3), Rebif
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Improving Prospective Memory Via Telehealth
Up to 70% of persons with multiple sclerosis (PwMS) experience cognitive impairment, which can have a significant impact on several aspects of their daily lives.
- Trial name
- TPMI (NCT05129293)
- Testing
- Prospective Memory Intervention, Educational
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Trinity Health Of New England
Relapsing-Remitting Multiple Sclerosis
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
Primary Objective is to assess the safety of extended treatment with Daclizumab High Yield Process (DAC HYP, BIIB019) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- SELECTED (NCT01051349)
- Testing
- BIIB019 (Daclizumab), trivalent seasonal influenza vaccine
- Where
- 65 sites in Czechia, Germany and 6 more
- Volunteers
- 410 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to…
- Trial name
- RADIANCE (NCT02047734)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 299 sites in United States, Belarus and 19 more
- Volunteers
- 1,320 people
- Sponsor
- Celgene
Multiple Sclerosis, Fatigue
MitoQ for Fatigue in Multiple Sclerosis (MS)
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo.
- Trial name
- MitoQ (NCT04267926)
- Testing
- 20 mg MitoQ, 40mg of MitoQ
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- VA Office of Research and Development
Relapsing-Remitting Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
- Trial name
- NCT04997148
- Where
- 8 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Osteoporosis, Multiple Sclerosis
Zoledronic Acid in MS-patients With Osteoporosis
This study is designed to evaluate the efficacy and safety of zoledronic acid 5 mg intravenous (i.v.) relative to placebo in Multiple Sclerosis (MS) patients with osteoporosis and to support the optimal use of zoledronic acid for…
- Trial name
- EXALT (NCT01166178)
- Testing
- Zoledronic Acid, Calcium and Vitamin D combination
- Where
- 15 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis
Multiple Sclerosis, Fatigue
A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
This study assesses the safety, tolerability, and efficacy of suvorexant in multiple sclerosis patients. Enrolled subjects will receive 2 weeks of treatment during treatment period 1 with either suvorexant or matching placebo…
- Conditions
- Multiple Sclerosis, Fatigue, Insomnia
- Trial name
- DREAM (NCT03110315)
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Theodore R. Brown, MD MPH
Relapsing-Remitting Multiple Sclerosis
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT00203021
- Testing
- Glatiramer acetate
- Where
- 11 sites in United States
- Volunteers
- 208 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Fatigue in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
This study evaluated the effect of an individualized web-based physical training in fingolimod -treated patients.
- Trial name
- PACE (NCT01490840)
- Testing
- Physical exercise
- Where
- 32 sites in Germany
- Volunteers
- 178 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China
The purpose of this study was to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.
- Trial name
- NCT05199571
- Testing
- Ofatumumab
- Where
- 18 sites in China
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis
The effects of multiple sclerosis (MS) on cognition, thought to occur in 50-75% of persons with MS, have gained increasing recognition as one of the major disabling symptoms of the disease.
- Trial name
- NCT03200899
- Testing
- MAPSS-MS, Usual Care plus computer games
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Texas at Austin
Multiple Sclerosis
Oral Cladribine B-cell Study
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells and Tregs
- Trial name
- NCT06415864
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Queen Mary University of London
Relapsing-remitting Multiple Sclerosis (RRMS)
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
- Trial name
- ASSESS (NCT01633112)
- Testing
- fingolimod, glatiramer acetate
- Where
- 130 sites in United States, Argentina and 5 more
- Volunteers
- 1,064 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression…
- Trial name
- Cognition (NCT01333501)
- Testing
- Fingolimod, Interferon beta 1b
- Where
- 26 sites in Germany, Italy
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI…
- Trial name
- NCT04879628
- Testing
- SAR441344 IV, SAR441344 SC, MRI contrast-enhancing preparations
- Where
- 37 sites in United States, Bulgaria and 8 more
- Volunteers
- 129 people
- Sponsor
- Sanofi
Systemic Sclerosis
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
- Trial name
- NCT04744207
- Testing
- GS-248
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 94 people
- Sponsor
- Gesynta Pharma AB
Multiple Sclerosis
Short-term B-cell Depletion in Relapsing Multiple Sclerosis
Several disease-modifying therapies (DMTs) have been shown to be effective in reducing the disease activity in patients with relapsing forms of multiple sclerosis (MS) but these treatments, often need to be used continuously for…
- Trial name
- NCT03853746
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University